Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization
Abstract Breast cancer became the most prevalent malignancy among women, and HER2 expression status is critical for treatment decisions. With the emergence of ADC drugs, HER2 low-expressing patients who previously did not respond well to traditional anti-HER2 therapies may now benefit. In this study...
Saved in:
| Main Authors: | Jingmin Zhong, Beibei Gao, Qingjie Wang, Jun He, Danjv Luo, Chen Zhang, Jun Fan, Xiu Nie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Diagnostic Pathology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13000-024-01594-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhancing HER2 testing in breast cancer: predicting fluorescence in situ hybridization (FISH) scores from immunohistochemistry images via deep learning
by: Daniel O Macaulay, et al.
Published: (2025-03-01) -
Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category
by: Ana Catharina Joaquim, et al.
Published: (2025-08-01) -
Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01) -
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
by: Sila Oksuz, et al.
Published: (2025-04-01) -
Interlaboratory variability of HER2 fluorescence in situ hybridization testing in breast cancer: results of a multicenter proficiency-testing ring study in China
by: Rongxue Peng, et al.
Published: (2024-12-01)